Lung Macrodissect AI

Lung Macrodissect AI is seamlessly integrated into the HALO AP® platform, an AI-driven solution tailored for anatomic pathology workflows. This integration facilitates efficient lung macrodissection processes, enhancing research capabilities.

While Lung Macrodissect AI is not classified as a medical device in the EU/UK and is not intended for diagnostic purposes, it is accessible through the HALO AP® enterprise digital pathology platform. In the USA, it is designated for research use only and lacks FDA clearance for clinical diagnostic applications.

The HALO AP® platform, which hosts Lung Macrodissect AI, is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland. It is also for research use only in the USA, without FDA clearance for clinical diagnostics. Notably, HALO AP® ensures compliance with FDA 21 CFR Part 11, HIPAA, and GDPR regulations.

Support and Services

• Technical support is available from IT specialists.
• Options for purchasing software maintenance and support plans are offered.
• Application scientists are ready to assist with product inquiries and purchases.

For those interested in exploring Lung Macrodissect AI further, live demos can be requested, and additional information about related clinical solutions is available. The platform supports various research and discovery areas, including image analysis and management, and offers services such as AI-powered image analysis and cloud services hosted on AWS.